1227628-78-5

Basic information

• Product Name: 5-BroMo-1H-pyrazolo[4,3-b]pyridine
• Synonyms: 5-BroMo-1H-pyrazolo[4,3-b]pyridine;5-broMo-1H-pyrazolo[4;5-BroMo-1H-pyrazolo[4,3-b...
• CAS NO: 1227628-78-5
• Molecular Formula: C6H4BrN3
• Molecular Weight: 198.02006
• Mol File: 1227628-78-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 351.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.894±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.68±0.40(Predicted)
• CAS DataBase Reference: 5-BroMo-1H-pyrazolo[4,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMo-1H-pyrazolo[4,3-b]pyridine(1227628-78-5)
• EPA Substance Registry System: 5-BroMo-1H-pyrazolo[4,3-b]pyridine(1227628-78-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 1227628-78-5(Hazardous Substances Data)

Usage

General Description

5-Bromo-1H-pyrazolo[4,3-b]pyridine is a chemical compound that belongs to the class of organic compounds known as pyrazolopyridines, which are aromatic heterocyclic compounds containing a pyrazole ring fused to a pyridine ring. The molecular formula of this compound is C6H4BrN3 and it is represented by the canonicalized SMILES string "C1=CC2=C(N1)N=CN=C2Br". 5-BroMo-1H-pyrazolo[4,3-b]pyridine doesn't have any known applications or uses, and specific physical properties or toxicity information may not be readily available. It might be used in chemical research or as an intermediate in the synthesis of other chemicals. However, given its potential reactivity due to the presence of bromine and nitrogen atoms, appropriate safety measures should be taken when handling this compound.

Upstream product

• 126325-47-1 3-amino-6-bromo-2-methylpyridine 
• 22282-96-8 6-bromo-2-methyl-3-nitro-pyridine 
• 110-46-3 isopentyl nitrite 

Downstream Products

• 1613638-99-5 (R)-2-phenyl-2-[5-(1H-pyrazolo[4,3-b]pyridin-5-yl)pyridin-3-ylamino]ethanol 

Relevant articles and documents

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.